Jazz Pharmaceuticals PLC $JAZZ Stock Purchased by Sowell Financial Services LLC

Sowell Financial Services LLC raised its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 501.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,458 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,219 shares during the quarter. Sowell Financial Services LLC’s holdings in Jazz Pharmaceuticals were worth $3,116,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Kendall Capital Management raised its position in shares of Jazz Pharmaceuticals by 8.9% during the third quarter. Kendall Capital Management now owns 10,584 shares of the specialty pharmaceutical company’s stock worth $2,450,000 after purchasing an additional 865 shares during the period. Evergreen Capital Management LLC grew its stake in Jazz Pharmaceuticals by 4.2% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,250 shares of the specialty pharmaceutical company’s stock valued at $521,000 after acquiring an additional 90 shares in the last quarter. Tectonic Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 3.3% during the third quarter. Tectonic Advisors LLC now owns 6,089 shares of the specialty pharmaceutical company’s stock worth $1,410,000 after purchasing an additional 193 shares during the period. Sterling Capital Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 2.9% during the 3rd quarter. Sterling Capital Management LLC now owns 17,846 shares of the specialty pharmaceutical company’s stock valued at $4,132,000 after acquiring an additional 509 shares in the last quarter. Finally, MBL Wealth LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $202,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 3.9%

Shares of JAZZ opened at $215.98 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38. The firm has a market capitalization of $14.02 billion, a PE ratio of 9.00, a price-to-earnings-growth ratio of 0.42 and a beta of 0.37. The stock’s fifty day simple moving average is $231.96 and its 200-day simple moving average is $216.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same quarter in the prior year, the firm earned ($8.25) EPS. The firm’s quarterly revenue was up 15.5% compared to the same quarter last year. As a group, research analysts predict that Jazz Pharmaceuticals PLC will post 10.87 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $230.33, for a total value of $1,381,980.00. Following the completion of the transaction, the director owned 345,875 shares of the company’s stock, valued at $79,665,388.75. The trade was a 1.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. The trade was a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 100,121 shares of company stock worth $24,855,802. Company insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on JAZZ shares. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. TD Cowen upped their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Robert W. Baird increased their price target on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Citigroup assumed coverage on Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They issued a “buy” rating and a $325.00 price target on the stock. Finally, Truist Financial lifted their price objective on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.05.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.